Figure 2.
Post-HCT outcomes for 583 adults with AML undergoing allogeneic HCT following myeloablative conditioning while in first or second morphologic remission, stratified by disease status at diagnosis (de novo vs. therapy-related vs. antecedent hematologic disorder): (A) Non-relapse mortality; (B) relapse; (C) relapse-free survival; and (D) overall survival.